J&J suffers setback over heart-stent price cap in U.K.

07/23/2008 | Bloomberg

The British National Institute for Health and Clinical Excellence has denied an appeal from Johnson & Johnson's Cordis unit against a ruling that limits the price of drug-coated stents to no more than $599 above the cost of bare-metal stents. Drug-eluting devices "will continue to be an important treatment option for patients who would be at high risk of requiring further interventions if a bare-metal stent was used instead," NICE CEO Andrew Dillon said.

View Full Article in:

Bloomberg

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
MGR CLINICAL RESEARCH - 14000003MB
Abbott
Santa Clara, CA
Senior Officer, Drugs and Medical Devices
The Pew Charitable Trusts
Washington, DC
Director of ASO Department
Bluegrass Family Health
Lexington-or could be in Nashville, TN, KY
Mgr NGS Provider Enrollment (I)
National Government Services - WellPoint
Harrisburg, PA
NGS Provider Enrollment Rep
National Government Services - WellPoint
Harrisburg, PA